Depending on the active alarmins within the TME, PD-1 expression is increased in the corresponding ILC subset (exogenous IL-33 in the case of ILC-2s, and melanoma tumor cell-derived lactate in case of T-bet+ ILCs). Here, IL33 is linked to melanoma.